Drawing for AMYLON

USPTO serial 79230909

AMYLON

Reviewed by CopyMark Law Group

Reg. 5688231Status 709
Filing date
Status date
Registration date
Mar 5, 2019
Examiner
CIANCI, RYAN MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AMYLON?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jess M. Collen

JESS M. COLLEN JESS M. COLLEN80 SOUTH HIGHLAND AVENUECOLLEN IPOSSINING, NY 10562

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for treating brain conditions; pharmaceutical compositions for treating brain conditions; pharmaceutical drugs for treating brain conditions; chemico-pharmaceutical preparations for treating brain conditions; sanitary preparations for medical purposesSECTION 71 - CANCELLED—
036Business fundraising for others; financial investment information; financial investment research; capital investment; venture capital funding services for inventors; venture capital funding services to emerging and start-up companiesSECTION 71 - CANCELLED—
042Laboratory research services relating to pharmaceuticals; medical research; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development in the field of biotechnology; biological research; clinical research in the field of biology and brain conditions; biomedical research services; pharmaceutical research services; research of pharmaceuticals; pharmaceutical products development; testing of pharmaceuticals; pharmaceutical drug development services; research and development of new products for the pharmaceutical industry; consultancy relating to pharmaceutical research and development; consultancy in the field of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trialsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 19, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 2, 2025CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Nov 22, 2025CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Nov 21, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 21, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 19, 2025C71TCANCELLED SECTION 71—
Mar 5, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 19, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 28, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 28, 2019FIMPFINAL DISPOSITION PROCESSED—
Jun 5, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 5, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 18, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 18, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 15, 2018GPNXNOTIFICATION PROCESSED BY IB—
Nov 28, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 28, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Nov 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 10, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 9, 2018ALIEASSIGNED TO LIE—
Oct 26, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 26, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Oct 26, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 26, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 26, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 17, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 16, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 16, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 30, 2018RFNTREFUSAL PROCESSED BY IB—
Jun 14, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 14, 2018RFRRREFUSAL PROCESSED BY MPU—
Jun 9, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 8, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 7, 2018DOCKASSIGNED TO EXAMINER—
May 4, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 30, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 26, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance